Italy· 045890023
PREVYMIS*28x1 cpr rivestite 480 mg
A letermovir product containing letermovir, registered in Italy by MERCK SHARP & DOHME BV, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.
Checked against the register on
Informational only — not a medical device.
Where it is registered
Letermovir is registered in 15 of 19 countries.
Countries holding a registration under ATC J05AX18 (letermovir), each read from that country’s own register.
- This record: Italy
- 10 of them publish a price we can compare per daily dose
Letermovir · ATC J05AX18
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of letermovir costs, country by country.
Normalised to the WHO defined daily dose (0.48 g), the median price runs from $9.77 in France to $563.69 in Italy — a ×58 gap.
- Italy: $563.69 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Letermovir · price per daily dose (0.48 g)
USD · FX 28 Sept 2026
- IT Italy$563.69
- CH Switzerland$371.41
- FR France$9.77
The record
At a glance
- Active substance
- Letermovir
- Manufacturer
- MERCK SHARP & DOHME BV
- Country
- Italy (IT)
- ATC code
- J05AX18
- ATC class
- Letermovir
- Defined daily dose
- 0.48 g, O
- Reimbursed
- Yes
- Last checked
- June 4, 2026
Packs & prices · 1
1 priced- aic045890023PREVYMIS*28x1 cpr rivestite 480 mgEUR 13863.36
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
222 interactions on record for letermovir.
Graded by severity as the source publishes them — 38 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Letermovir · interactions on record
222 records
- 38 severe
- 172 moderate
- 12 minor
Most severe, free to view
- CisaprideA03FA02severe
- NaloxegolA06AH03severe
- EliglustatA16AX10severe
- CilostazolB01AC23severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Letermovir in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandPREVYMISOrifarm Oy
- SwitzerlandPrevymis 120 mg, GranulatMSD Merck Sharp & Dohme AG
- CzechiaPREVYMISMerck Sharp & Dohme B.V., Haarlem
- United StatesPREVYMISMerck Sharp & Dohme LLC
- FrancePREVYMIS 120 mg, granulés en sachetMERCK SHARP & DOHME (PAYS-BAS)
- IrelandPREVYMIS 120 mg granules in sachetMerck Sharp & Dohme BV,
- IcelandPrevymisMerck Sharp & Dohme B.V.*
- NetherlandsPrevymis 120 mg granulaat in sachetMerck Sharp & Dohme B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Prevymis
- Liechtenstein · Prevymis
- Norway · Prevymis
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c0fa6603-e41e-45fe-b080-bd9f59bde92c GET /v1/drugs/c0fa6603-e41e-45fe-b080-bd9f59bde92c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"price": 13863.36,
"source": "aifa",
"currency": "EUR",
"strength": "LETERMOVIR 480MG 28 UNITA' USO ORALE",
"substance": "Letermovir",
"equivalence_group": "KNO",
"transparency_flag": null
}See everything about letermovir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.